Key Dates

Related Announcements

• November 20, 2024 - Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed). See NOFO RFA-DA-26-034.
• April 16, 2019 - NHLBI Limitations on Clinical Trial Applications Submitted to the NIH Parent (R01 Clinical Trial Required) Funding Opportunity Announcement (FOA). See NOFO NOT-HL-19-690.

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that effective immediately the National Heart, Lung, and Blood Institute (NHLBI) will participate in RFA-DA-26-034, "Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)".

The following text in bold and italics has been added to reflect NHLBI's participation:

Part 1. Overview Information

Components of Participating Organizations

National Institute on Drug Abuse (NIDA)

National Institute of Allergy and Infectious Diseases (NIAID)

National Heart, Lung, and Blood Institute (NHLBI)

Assistance Listing Number(s)

93.279, 93.855, 93.837, 93.838, 93.839, 93.840, 93.233

Section VII. Agency Contacts

Division of Lung Diseases
National Heart, Lung, and Blood Institute (NHLBI)
Email: [email protected]
Subject: RFA-DA-26-034

Office of Grants Management
National Heart, Lung, and Blood Institute (NHLBI)
Email: [email protected]
Subject: RFA-DA-26-034

All other aspects of the NOFO remain the same.
 

Inquiries

Please direct all inquiries regarding this Notice to:

Scientific/Research Contact(s)

Division of Lung Diseases
National Heart, Lung, and Blood Institute (NHLBI)
Email: [email protected]
Subject: RFA-DA-26-034

Financial/Grants Management Contact(s)

Office of Grants Management
National Heart, Lung, and Blood Institute (NHLBI)
Email: [email protected]
Subject: RFA-DA-26-034